Perspectives

All Case Studies Views Resources Whitepapers Podcasts On-Demand Webinars
Modeling To Inform Payer Communications and Policy – Optimizing Treatment Sequences in Multiple Immunology Indications
Health systems view low-cost therapeutic alternatives (biosimilars and generics) as opportunities to reduce their medicine spend. However, this approach focuses on costs only and not outcomes, which results in the adoption of ‘low-cost first’ blanket policies regardless of biologic class or therapy area. Consequently, patients are left to cycle through low-cost options before they can access the most effective treatments
Case Study Feb 18, 2022
Syndicated Offerings: Sonar & Engage
Our newly developed syndicated research program is designed to assist in meeting your strategic objectives at key stages of product lifecycle, building upon our extensive experience in both the digital and healthcare space.
Resource
HTA for Precision Medicines: Evaluating the Impact of Testing Practices, Prognostic Markers, and Other Elements of Value
The market for precision medicine has grown exponentially and continues to grow. Precision medicine considers individual patient characteristics such as their genes, environments and lifestyles to provide tailored treatment options. In this article, we explore the key areas relevant to the economic evaluation of precision medicines and offer practical modelling recommendations based on our experience.
Whitepaper Jan 7, 2022